Prudent use of antibiotics: Are our expectations justified?

Clinical Infectious Diseases

Volumn 33, Issue SUPPL. 3, 2001, Pages

  Phillips, I ^a  

^a NONE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AVOPARCIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; CHRONIC BRONCHITIS; CONFERENCE PAPER; ESCHERICHIA COLI; HEALTH CARE POLICY; HOSPITAL INFECTION; HUMAN; OTITIS MEDIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS PYOGENES; VETERINARY MEDICINE;

ANIMALS; ANTI-BACTERIAL AGENTS; DRUG AND NARCOTIC CONTROL; DRUG RESISTANCE, MICROBIAL; HUMANS; PRESCRIPTIONS, DRUG;

EID: 0035885058     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/321838     Document Type: Conference Paper

References (17)

1. Preface
2. Antibiotic policies
3. Advances in antibacterial chemotherapy
4. Antibiotic clinical trials: The Witley Park symposium
5. Lessons from the past: A personal view
6. Antibiotic prescribing and antibiotic resistance in community practice: Retrospective study, 1996-8
7. Antibiotic resistant Staphylococcus aureus and hospital antibiotic policies
8. The subtleties of antibiotic resistance
9. The effects of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland
10. Assessing the evidence that antibiotic growth promoters influence human infections
11. Reducing antibiotic resistance
12. Antibiotic resistance: The road of no return
13. 1me plasmids in multiply antimicrobial-resistant Escherichia coli from urinary tract infection
14. Can susceptibility to an antimicrobial be restored by halting its use? The case of streptomycin versus Enterobacteriaceae
15. Extensive persistence of vancomycin-resistant enterococci on Norwegian poultry farms 3 years after the avoparcin ban
16. The use of bacitracin as a growth promoter in animals produces no risk to human health